Vitrolife (VITR) Panoramica del titolo
Vitrolife AB (publ) fornisce prodotti per la riproduzione assistita in Europa, Medio Oriente, Africa, Asia-Pacifico e Americhe. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 5/6 |
| Crescita futura | 4/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 4/6 |
| Dividendi | 2/6 |
Premi
Analisi del rischio
Non sono stati rilevati rischi per VITR dai nostri controlli di rischio.
VITR Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Vitrolife AB (publ)
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | SEK 87.95 |
| Massimo di 52 settimane | SEK 153.50 |
| Minimo di 52 settimane | SEK 84.60 |
| Beta | 1.7 |
| Variazione di 1 mese | -15.76% |
| Variazione a 3 mesi | -5.28% |
| Variazione di 1 anno | -35.00% |
| Variazione a 3 anni | -57.55% |
| Variazione a 5 anni | -75.27% |
| Variazione dall'IPO | 1,138.73% |
Notizie e aggiornamenti recenti
Aggiornamento della narrazione • Jun 16
VITR: Governance Reforms And Softer Street Sentiment Will Support Future Upside Potential
Analysts have trimmed their price expectations for Vitrolife, with the consensus target moving slightly lower to SEK 162.75 as some now see a more cautious outlook following recent downgrades. Key valuation inputs such as the discount rate and assumed future P/E have been adjusted only marginally.Aggiornamento della narrazione • Jun 01
VITR: Governance Reforms And Softer Street Sentiment Will Support Future Upside Potential
Analysts have trimmed their price target on Vitrolife to SEK162.75 from SEK172.20, citing slightly higher discount rate assumptions, more cautious revenue growth expectations, softer profit margin estimates, and a modestly lower future P/E multiple following recent bearish Street research, including a downgrade from Pareto. What's in the News CEO Bronwyn Brophy O'Connor has resigned to take a CEO role elsewhere in the medtech industry, and the Board has started a recruitment process for a new CEO.Aggiornamento della narrazione • May 12
VITR: Governance Reforms And Higher P/E Expectations Will Support Future Upside Potential
Vitrolife's analyst price target has been adjusted from SEK 162.67 to SEK 172.20. Analysts point to modest tweaks in fair value assumptions, discount rate, revenue growth, profit margin and future P/E forecasts, even as some research houses, such as Pareto, have turned more cautious on the stock.Recent updates
Aggiornamento della narrazione • Jun 16
VITR: Governance Reforms And Softer Street Sentiment Will Support Future Upside Potential
Analysts have trimmed their price expectations for Vitrolife, with the consensus target moving slightly lower to SEK 162.75 as some now see a more cautious outlook following recent downgrades. Key valuation inputs such as the discount rate and assumed future P/E have been adjusted only marginally.Aggiornamento della narrazione • Jun 01
VITR: Governance Reforms And Softer Street Sentiment Will Support Future Upside Potential
Analysts have trimmed their price target on Vitrolife to SEK162.75 from SEK172.20, citing slightly higher discount rate assumptions, more cautious revenue growth expectations, softer profit margin estimates, and a modestly lower future P/E multiple following recent bearish Street research, including a downgrade from Pareto. What's in the News CEO Bronwyn Brophy O'Connor has resigned to take a CEO role elsewhere in the medtech industry, and the Board has started a recruitment process for a new CEO.Aggiornamento della narrazione • May 12
VITR: Governance Reforms And Higher P/E Expectations Will Support Future Upside Potential
Vitrolife's analyst price target has been adjusted from SEK 162.67 to SEK 172.20. Analysts point to modest tweaks in fair value assumptions, discount rate, revenue growth, profit margin and future P/E forecasts, even as some research houses, such as Pareto, have turned more cautious on the stock.Aggiornamento della narrazione • Apr 27
VITR: Governance Reforms And Reset Expectations Will Support Future Upside Potential
Vitrolife’s analyst price target has been trimmed slightly from SEK 163.40 to about SEK 162.70, as analysts factor in updated assumptions on growth, margins and future P/E, and reflect the more cautious tone seen in recent research such as Pareto’s downgrade. Analyst Commentary Bullish Takeaways Bullish analysts see the revised target near SEK 162.70 as still implying upside relative to where caution has already been factored into growth, margin and P/E assumptions.Aggiornamento della narrazione • Apr 12
VITR: Governance Amendments And Steady Assumptions Will Support Future Upside
Analysts have reduced their price target for Vitrolife to SEK 163.40 from SEK 176.75, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News Vitrolife AB (publ) has proposed amendments to its Articles of Association to be decided at the Annual General Meeting scheduled for May 5, 2026.Aggiornamento della narrazione • Mar 29
VITR: Stable Fair Value And Tweaked Assumptions Will Support Future Upside
Analysts have kept Vitrolife's fair value estimate broadly unchanged at SEK 176.75, with only minor tweaks to inputs such as the discount rate, revenue growth, profit margin, and future P/E assumptions, which has driven a very small adjustment to their price target framework. Valuation Changes Fair Value Estimate was kept stable at SEK 176.75, indicating no change in the central valuation outcome.Aggiornamento della narrazione • Mar 13
VITR: Genetic Services Restructuring And Impairment Will Underpin Future Upside Potential
Analysts have kept their SEK 176.75 price target for Vitrolife broadly unchanged, making only very small adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions to reflect fine tuning in their models rather than a shift in their overall view. What's in the News Vitrolife plans to record a goodwill impairment of SEK 5.4b in the fourth quarter of 2025, tied to the Igenomix acquisition (company announcement).Aggiornamento della narrazione • Feb 26
VITR: Genetic Services Restructuring And Impairment Will Support Future Upside Potential
Analysts have left their SEK 176.75 price target for Vitrolife unchanged, with only minimal tweaks to inputs such as discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Vitrolife plans to record a goodwill impairment of SEK 5.4b in the fourth quarter of 2025, linked to the Igenomix acquisition (company announcement).Aggiornamento della narrazione • Feb 11
VITR: Restructuring Of Genetic Services Will Drive Future Upside Potential
Analysts have trimmed their price target on Vitrolife to €176.75 from €187, reflecting updated assumptions that include a higher discount rate, a higher future P/E multiple, and revised expectations for revenue growth and profit margins. What's in the News Vitrolife plans to record a goodwill impairment of SEK 5.4b in the fourth quarter of 2025, linked to the Igenomix acquisition (Key Developments).Aggiornamento della narrazione • Jan 27
VITR: Restructuring And Goodwill Impairment Will Drive Future Upside Potential
Analysts have trimmed their price target on Vitrolife from SEK188.75 to SEK187.00, reflecting adjustments to revenue growth and discount rate assumptions, along with updated views on profit margin and future P/E levels. What's in the News Vitrolife plans a restructuring program for its genetic services business, targeting annualised savings of SEK 65 million.Aggiornamento della narrazione • Jan 10
VITR: Restructuring And Goodwill Impairment Will Support Future Upside Potential
Analysts have maintained their fair value estimate for Vitrolife at SEK 188.75, with only minor technical adjustments to the discount rate and future P/E assumptions shaping the updated price target narrative. What's in the News Vitrolife plans to record a goodwill impairment of SEK 5.4b in the fourth quarter of 2025, related to the Igenomix acquisition (company announcement).Aggiornamento della narrazione • Dec 25
VITR: Restructuring And Goodwill Impairment Will Support Future Upside Potential
Analysts have slightly reduced their price target on Vitrolife, trimming fair value by SEK 4.75 to SEK 188.75, as modestly higher long term growth assumptions are offset by a small downgrade to profitability and a lower expected valuation multiple. What's in the News Vitrolife plans to record a SEK 5.4 billion goodwill impairment in the fourth quarter of 2025 related to the Igenomix acquisition (company announcement).Articolo di analisi • Dec 18
There's No Escaping Vitrolife AB (publ)'s (STO:VITR) Muted Revenues
Vitrolife AB (publ)'s ( STO:VITR ) price-to-sales (or "P/S") ratio of 5.2x might make it look like a buy right now...Aggiornamento della narrazione • Dec 11
VITR: Higher Long Term Revenue Outlook Will Support Further Upside
Analysts have nudged their price target on Vitrolife slightly higher to SEK 193.50 from SEK 193.00, citing marginally stronger long term revenue growth expectations that more than offset a modest uptick in the assumed discount rate and a slightly lower forecast profit margin. Valuation Changes Fair Value Estimate: unchanged at SEK 193.5 per share, indicating no revision to the intrinsic value despite minor model adjustments.Aggiornamento della narrazione • Nov 27
VITR: Current Metrics And Stable Margins Will Support Further Upside
Analysts have maintained their fair value price target for Vitrolife at SEK 193.50, citing steady expectations for the company's growth, profitability, and valuation metrics. Valuation Changes Consensus Analyst Price Target: Unchanged at SEK 193.50.Articolo di analisi • Nov 26
Vitrolife (STO:VITR) Seems To Use Debt Quite Sensibly
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Aggiornamento della narrazione • Nov 11
VITR: Stable Profitability And Marginal Rate Shift Will Drive Future Upside
Narrative Update on Vitrolife Analyst Price Target Vitrolife's analyst price target remains unchanged at SEK 193.50. Analysts cite only minor adjustments in growth and profitability forecasts, affirming their previous valuation stance.Aggiornamento della narrazione • Oct 28
Profit Margins And Revenue Outlook Will Support Recovery Trends Ahead
Narrative Update on Vitrolife Analyst Price Target Analysts have raised Vitrolife’s fair value estimate from SEK191.75 to SEK193.50. They highlight the company's improved profit margin outlook and stronger projected revenue growth as key drivers behind the revised target.Articolo di analisi • Oct 28
Vitrolife AB (publ) (STO:VITR) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Investors in Vitrolife AB (publ) ( STO:VITR ) had a good week, as its shares rose 6.6% to close at kr151 following the...Aggiornamento della narrazione • Oct 14
US IVF Treatment Rebound And APAC Reimbursements Will Drive Recovery
Analysts have lowered their price target for Vitrolife from SEK 202.50 to SEK 191.75. This reflects updated expectations for slower revenue growth and profit margins, as well as a slightly higher discount rate.Articolo di analisi • Aug 25
Vitrolife AB (publ)'s (STO:VITR) Shares Lagging The Industry But So Is The Business
Vitrolife AB (publ)'s ( STO:VITR ) price-to-sales (or "P/S") ratio of 5.3x might make it look like a strong buy right...Nuova narrazione • Jul 28
US IVF Treatment Rebound And APAC Reimbursements Will Drive Recovery
Recovery in IVF procedure volume and expansion in key regions will drive organic revenue growth and margin improvement as market conditions stabilize.Articolo di analisi • Jul 08
Vitrolife AB (publ)'s (STO:VITR) Intrinsic Value Is Potentially 68% Above Its Share Price
Key Insights Vitrolife's estimated fair value is kr242 based on 2 Stage Free Cash Flow to Equity Current share price of...Articolo di analisi • Jun 20
Here's Why Vitrolife (STO:VITR) Can Manage Its Debt Responsibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Articolo di analisi • Apr 25
Vitrolife AB (publ)'s (STO:VITR) Price Is Right But Growth Is Lacking
Vitrolife AB (publ)'s ( STO:VITR ) price-to-sales (or "P/S") ratio of 5.4x might make it look like a buy right now...Articolo di analisi • Mar 13
Here's Why Vitrolife (STO:VITR) Can Manage Its Debt Responsibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Feb 20
Estimating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)
Key Insights Vitrolife's estimated fair value is kr216 based on 2 Stage Free Cash Flow to Equity Vitrolife's kr213...Articolo di analisi • Nov 27
Is Vitrolife (STO:VITR) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • Aug 21
Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Vitrolife fair value estimate is kr204 Current share price of...Articolo di analisi • Jul 20
Vitrolife AB (publ) Just Beat EPS By 16%: Here's What Analysts Think Will Happen Next
Vitrolife AB (publ) ( STO:VITR ) just released its quarterly report and things are looking bullish. Vitrolife beat...Articolo di analisi • Jul 18
Vitrolife AB (publ) (STO:VITR) Shares Fly 32% But Investors Aren't Buying For Growth
The Vitrolife AB (publ) ( STO:VITR ) share price has done very well over the last month, posting an excellent gain of...Articolo di analisi • Apr 03
Vitrolife (STO:VITR) Is Carrying A Fair Bit Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Mar 07
A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Vitrolife fair value estimate is kr215 With kr186 share price...Articolo di analisi • Feb 05
Vitrolife AB (publ) Just Missed Earnings; Here's What Analysts Are Forecasting Now
The yearly results for Vitrolife AB (publ) ( STO:VITR ) were released last week, making it a good time to revisit its...Articolo di analisi • Jan 05
Vitrolife AB (publ)'s (STO:VITR) Share Price Matching Investor Opinion
With a price-to-earnings (or "P/E") ratio of 62.5x Vitrolife AB (publ) ( STO:VITR ) may be sending very bearish signals...Articolo di analisi • Dec 15
Here's Why We Think Vitrolife (STO:VITR) Is Well Worth Watching
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Articolo di analisi • Nov 27
Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)
Key Insights Vitrolife's estimated fair value is kr193 based on 2 Stage Free Cash Flow to Equity With kr173 share...Articolo di analisi • Nov 06
Is Vitrolife (STO:VITR) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Articolo di analisi • Aug 25
An Intrinsic Calculation For Vitrolife AB (publ) (STO:VITR) Suggests It's 27% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, Vitrolife fair value estimate is kr202 Current share price of...Rendimenti per gli azionisti
| VITR | SE Biotechs | SE Mercato | |
|---|---|---|---|
| 7D | -5.0% | 4.6% | -0.8% |
| 1Y | -35.0% | 33.2% | 13.3% |
Ritorno vs Industria: VITR ha avuto una performance inferiore rispetto al Swedish Biotechs che ha registrato un rendimento 33.2 % nell'ultimo anno.
Rendimento vs Mercato: VITR ha avuto una performance inferiore al mercato Swedish che ha registrato un rendimento 13.3 % nell'ultimo anno.
Volatilità dei prezzi
| VITR volatility | |
|---|---|
| VITR Average Weekly Movement | 5.9% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in SE Market | 13.7% |
| 10% least volatile stocks in SE Market | 3.5% |
Prezzo delle azioni stabile: VITR non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Swedish.
Volatilità nel tempo: La volatilità settimanale ( 6% ) di VITR è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1989 | 1,126 | Bronwyn Brophy O´Connor | www.vitrolife.com |
Vitrolife AB (publ) fornisce prodotti per la riproduzione assistita in Europa, Medio Oriente, Africa, Asia-Pacifico e Americhe. Offre aghi per il trattamento degli spermatozoi, aghi per il prelievo degli ovociti, pipette per la micromanipolazione, sistemi time-lapse e strumenti di valutazione, sistemi laser e di imaging, supporti e oli per la FIV, trasferimento di embrioni, crioconservazione e kit di genomica. L'azienda fornisce anche prodotti eWitness e Labware, come piatti, pipette, provette e VitroTemp.
Vitrolife AB (publ) Riepilogo dei fondamenti
| VITR statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | SEK 11.91b |
| Utili (TTM) | -SEK 5.01b |
| Ricavi(TTM) | SEK 3.41b |
3.5x
Rapporto P/S-2.4x
Rapporto P/EVITR è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| VITR Conto economico (TTM) | |
|---|---|
| Ricavi | SEK 3.41b |
| Costo del fatturato | SEK 1.41b |
| Profitto lordo | SEK 2.00b |
| Altre spese | SEK 7.01b |
| Utili | -SEK 5.01b |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
Jul 16, 2026
| Utile per azione (EPS) | -37.00 |
| Margine lordo | 58.65% |
| Margine di profitto netto | -147.17% |
| Rapporto debito/patrimonio netto | 18.0% |
Come si è comportato VITR nel lungo periodo?
Vedi performance storica e confrontoDividendi
1.3%
Rendimento attuale del dividendo-3%
Rapporto di remunerazioneAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/24 07:01 |
| Prezzo dell'azione a fine giornata | 2026/06/24 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Vitrolife AB (publ) è coperta da 11 analisti. 5 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| null null | ABG Sundal Collier |
| Kallum Titchmarsh | BofA Global Research |
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |